RxDoctor Payments Data

Sadeem Mahmood, MD

Cardiovascular Disease · Pine Bluff, ARNPI 1245299924

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $8,488 of the $10,683 with a category attached, or 79.5%. It is spread thinly across 38 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,322 and has fallen 53.3% since, to $1,084 in 2025.

$10,683in general payments, 2019–2025

Across 326 payments — averaging $32.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Biotronik Inc.$2K
  • Abbott$2K
  • Terumo Medical Corporation$700
  • Amgen$590
  • Siemens Medical Solutions USA, Inc.$533
  • plus $4K from 32 others
$2,368in research payments, 2019–2025

Across 1 payment — averaging $2368.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$2K

What the payments were for

  • Consulting fees$7007%
  • Travel & lodging$1,47814%
  • Food & beverage$8,48879%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,683 in reported general payments places this provider in the 80th percentile of 130 cardiovascular disease providers in Arkansas.

See all cardiovascular disease providers in Arkansas

Medicare billing

Part B allowed, 2024
$532,816
Medicare patients
440
Services billed
4,057

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban264$166,307
EntrestoSacubitril/Valsartan86$84,071
EliquisApixaban42$32,838
FarxigaDapagliflozin Propanediol29$24,261
Repatha SureclickEvolocumab21$22,485
JardianceEmpagliflozin23$18,144
Praluent PenAlirocumab14$10,421
BrilintaTicagrelor14$9,841
Repatha SyringeEvolocumab11$9,552
Ranolazine ErRanolazine33$2,072
ClopidogrelClopidogrel Bisulfate353$1,978
Nebivolol Hcl36$1,188
Metoprolol Succinate83$939
Valsartan34$895
Rosuvastatin Calcium126$811

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$377$166,307264 claims
NovartisEntresto$440$84,07186 claims
AstraZenecaFarxiga, Brilinta$65$34,10243 claims
PfizerEliquis$35$32,83842 claims
Boehringer IngelheimJardiance$150$18,14423 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 130 cardiovascular disease providers in Arkansas.

Other cardiovascular disease in Pine Bluff

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →